Prolonged interleukin-2 (IL-2) treatment can augment immune activation without enhancing antitumor activity in renal cell carcinoma.

Sosman JA, Hank JA, Moore KH, Borchert A, Schell K, Kohler PC, Goldstein D, Bechhofer R, Storer B, Albertini MR
Cancer Invest. 1991 9 (1): 35-48

PMID: 2012995 · DOI:10.3109/07357909109032798

MeSH Terms (17)

Adult Aged Carcinoma, Renal Cell Cytotoxicity, Immunologic Drug Administration Schedule Female Humans Hypotension Interleukin-2 Kidney Neoplasms Killer Cells, Lymphokine-Activated Killer Cells, Natural Leukocytosis Male Middle Aged Pilot Projects Recombinant Proteins

Connections (1)

This publication is referenced by other Labnodes entities:

Links